Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity lowers target price on Castings

(Sharecast News) - Analysts at Canaccord Genuity lowered their target price on metal fabricator Castings from 340.0p to 325.0p on Thursday as it said things were "tough out there". Canaccord Genuity revised its estimates to reflect Castings' Tuesday trading for the year ending 31 March, which reported that core heavy truck customer demand schedules saw a further material reduction from mid-Q3, having previously fallen 20% year-on-year on an underlying market normalisation through H1.

More recently, Canaccord Genuity noted that Castings has seen Q4 volumes come back up to H1 levels as OEMs reported improving order intake, meaning there were tentative signs of volume growth through to Spring backed by rising sales volumes.

"While this underlying trading pattern results in a downgrade on its own, this has been compounded by two additional headwinds which we think impacts profits by a further ~£3.0m combined in FY25E, but which are not expected to recur in FY26E," said Canaccord.

The Canadian bank said that the first was enforced penalties on unused electricity volumes that had been forward purchased, and the second was start-up and trading losses in Castings' new Scunthorpe business.

"Our revised FY25E adjusted PBT/EPS estimates are therefore set 45% lower at £5.5m/9.4p with net cash down 33% to £10.6m. Importantly this sees the balance sheet in a strong and healthy position after significant capex and dividend distributions were made through the year," said the analysts, who reiterated their 'buy' rating on the stock.

"In addition, we prudently factor in a slower underlying market recovery in our FY26E/27E volume assumptions given low visibility."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.